SCHEMBL2596045

SCHEMBL2596045

NC(=O)CNS(=O)(=O)c1ccc2nccc(Nc3ccc4scnc4c3)c2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 7/20 0.68
KDR P35968 2/20 0.68
RIPK3 Q9Y572 4/20 0.65
RIPK1 Q13546 3/20 0.65
EGFR P00533 1/20 0.47
TGFBR1 P36897 1/20 0.47
BRAF P15056 1/20 0.43
PDGFRA P16234 1/20 0.43
ACVR1B P36896 1/20 0.43
PIK3CA P42336 1/20 0.43
PDE4B Q07343 1/20 0.42
RET P07949 1/20 0.41
CA9 Q16790 1/20 0.39
GAK O14976 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594634 0.91 RIPK2 (0.66) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2595855 0.88 RIPK2 (0.71) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2595384 0.85 RIPK2 (0.71) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL14718096 0.84 RIPK2 (0.70) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2591634 0.83 RIPK2 (0.80) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2596106 0.83 RIPK2 (0.68) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2596197 0.83 RIPK2 (0.74) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL14727598 0.83 RIPK2 (0.76) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2595771 0.83 RIPK2 (0.73) RIPK2KDRRIPK3RIPK1EGFR
SCHEMBL2595241 0.83 RIPK2 (0.69) RIPK2KDRRIPK3RIPK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP disclosed
EP-2566477-A1 AMINO-QUINOLINES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-03-13 EP disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
WO-2011140442-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-10 WO disclosed
WO-2011140442-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KDR 404/4885RIPK3 421/4885
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KDR 404/4885RIPK3 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.